Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders
Aim. To perform a population analysis of Non-High Density Lipoprotein Cholesterol level (non-HDL-c) in Russian population and to evaluate its association with cardiovascular events.Material and Methods. The material consisted of results obtained from 11 regions of the ESSE-RF1 Study and from 4 regio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2022-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2784 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227515219935232 |
|---|---|
| author | S. A. Shalnova V. A. Metelskaya V. A. Kutsenko E. B. Yarovaya A. V. Kapustina G. A. Muromtseva G. E. Svinin Yu. A. Balanova A. E. Imaeva S. E. Evstifeeva V. G. Vilkov O. L. Barbarash O. A. Belova Yu. I. Grinshtein A. Yu. Efanov O. N. Kalachikova N. V. Kulakova O. P. Rotar I. A. Trubacheva D. V. Duplyakov R. A. Libis I. A. Viktorova A. N. Redko S. S. Yakushin S. A. Boytsov E. V. Shlyakhto O. M. Drapkina |
| author_facet | S. A. Shalnova V. A. Metelskaya V. A. Kutsenko E. B. Yarovaya A. V. Kapustina G. A. Muromtseva G. E. Svinin Yu. A. Balanova A. E. Imaeva S. E. Evstifeeva V. G. Vilkov O. L. Barbarash O. A. Belova Yu. I. Grinshtein A. Yu. Efanov O. N. Kalachikova N. V. Kulakova O. P. Rotar I. A. Trubacheva D. V. Duplyakov R. A. Libis I. A. Viktorova A. N. Redko S. S. Yakushin S. A. Boytsov E. V. Shlyakhto O. M. Drapkina |
| author_sort | S. A. Shalnova |
| collection | DOAJ |
| description | Aim. To perform a population analysis of Non-High Density Lipoprotein Cholesterol level (non-HDL-c) in Russian population and to evaluate its association with cardiovascular events.Material and Methods. The material consisted of results obtained from 11 regions of the ESSE-RF1 Study and from 4 regions of the ESSE-RF2 Study. Study protocols were identical. The studies were performed in 2012-2014 and 2017, respectively. Endpoints were assessed in 19041 people aged 35-64 years. The median follow-up was 6.5 years in ESSE RF (1) and 3.8 years in ESSE RF(2). Analysis was performed for three lipid variables: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-HDLC in two samples: the general population sample and the same sample without individuals with coronary heart disease (CHD), myocardial infarction (MI) and/or stroke history and not taking statins (the population sample of "without a history of cardiovascular diseases [CVD]". The analysis of nonlinear associations was performed using the generalized additive Cox model. The combined cardiovascular endpoint was represented by cardiovascular death and nonfatal MI and stroke. Traditional and laboratory FRs, socio-demographic parameters were analyzed. The significance level for all tested hypotheses was set to be 0.05.Results. The prevalence of elevated non-HDL-C level (>3.7 mmol/l) was found to be 74.6%. No gender differences were found: there was 74.6% for men and 74.5% for women. Both mean values and prevalence of elevated non-HDL-C were increased with age in women, and its level was slightly decreased in men after 55 years old. Almost all analyzed RFs were significantly associated with elevated non-HDL-C in these two population samples. In both samples elevated total CH and elevated LDL-C were associated with all-cause mortality after correction for all RFs. On the contrary, the non-HDL-C was associated with CVD combined end pints. It has been shown that the risk of these end points increases uniformly with increase in levels of non HDL cholesterol, no nonlinear associations were found.Conclusion. The results of a population-based analysis of non-HDL-C performed in the Russian population for the first time confirmed that elevated non-HDL-C levels contribute significantly to determining the risk of cardiovascular events in the medium term. It can be assumed that the new risk scales (SCORE2 and SCORE OP) proposed by the European Society of Cardiology and the European Society of Preventive Cardiology, which include non-HDL C instead of TC, will allow adequate assessment of 10-year cardiovascular risk for Russians. However, continued monitoring of endpoints in order to obtain stable associations is required. |
| format | Article |
| id | doaj-art-8b23ec99f4cb49948b5b1cde1f24be10 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2022-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-8b23ec99f4cb49948b5b1cde1f24be102025-08-23T10:00:35ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532022-09-0118436637510.20996/1819-6446-2022-07-012041Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism DisordersS. A. Shalnova0V. A. Metelskaya1V. A. Kutsenko2E. B. Yarovaya3A. V. Kapustina4G. A. Muromtseva5G. E. Svinin6Yu. A. Balanova7A. E. Imaeva8S. E. Evstifeeva9V. G. Vilkov10O. L. Barbarash11O. A. Belova12Yu. I. Grinshtein13A. Yu. Efanov14O. N. Kalachikova15N. V. Kulakova16O. P. Rotar17I. A. Trubacheva18D. V. Duplyakov19R. A. Libis20I. A. Viktorova21A. N. Redko22S. S. Yakushin23S. A. Boytsov24E. V. Shlyakhto25O. M. Drapkina26National Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State UniversityNational Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State UniversityNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineKuzbass Cardiology CenterOBUZ Cardiology DispensaryProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityTyumen Medical UniversityVologda Research Center of the Russian Academy of SciencesPacific State Medical UniversityAlmazov National Medical Research CenterTomsk National Research Medical Center of the Russian Academy of Sciences, Cardiology Research InstituteOrenburg State Medical UniversitySamara State Medical UniversityOmsk State Medical UniversityKuban State Medical UniversityRyazan State Medical University named after academician I.P. PavlovNational Medical Research Center of Cardiology named after academician E.I. ChazovAlmazov National Medical Research CenterNational Medical Research Center for Therapy and Preventive MedicineAim. To perform a population analysis of Non-High Density Lipoprotein Cholesterol level (non-HDL-c) in Russian population and to evaluate its association with cardiovascular events.Material and Methods. The material consisted of results obtained from 11 regions of the ESSE-RF1 Study and from 4 regions of the ESSE-RF2 Study. Study protocols were identical. The studies were performed in 2012-2014 and 2017, respectively. Endpoints were assessed in 19041 people aged 35-64 years. The median follow-up was 6.5 years in ESSE RF (1) and 3.8 years in ESSE RF(2). Analysis was performed for three lipid variables: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-HDLC in two samples: the general population sample and the same sample without individuals with coronary heart disease (CHD), myocardial infarction (MI) and/or stroke history and not taking statins (the population sample of "without a history of cardiovascular diseases [CVD]". The analysis of nonlinear associations was performed using the generalized additive Cox model. The combined cardiovascular endpoint was represented by cardiovascular death and nonfatal MI and stroke. Traditional and laboratory FRs, socio-demographic parameters were analyzed. The significance level for all tested hypotheses was set to be 0.05.Results. The prevalence of elevated non-HDL-C level (>3.7 mmol/l) was found to be 74.6%. No gender differences were found: there was 74.6% for men and 74.5% for women. Both mean values and prevalence of elevated non-HDL-C were increased with age in women, and its level was slightly decreased in men after 55 years old. Almost all analyzed RFs were significantly associated with elevated non-HDL-C in these two population samples. In both samples elevated total CH and elevated LDL-C were associated with all-cause mortality after correction for all RFs. On the contrary, the non-HDL-C was associated with CVD combined end pints. It has been shown that the risk of these end points increases uniformly with increase in levels of non HDL cholesterol, no nonlinear associations were found.Conclusion. The results of a population-based analysis of non-HDL-C performed in the Russian population for the first time confirmed that elevated non-HDL-C levels contribute significantly to determining the risk of cardiovascular events in the medium term. It can be assumed that the new risk scales (SCORE2 and SCORE OP) proposed by the European Society of Cardiology and the European Society of Preventive Cardiology, which include non-HDL C instead of TC, will allow adequate assessment of 10-year cardiovascular risk for Russians. However, continued monitoring of endpoints in order to obtain stable associations is required.https://www.rpcardio.online/jour/article/view/2784population-based studynon-high-density lipoprotein cholesterolcardiovascular riskesse-rf study |
| spellingShingle | S. A. Shalnova V. A. Metelskaya V. A. Kutsenko E. B. Yarovaya A. V. Kapustina G. A. Muromtseva G. E. Svinin Yu. A. Balanova A. E. Imaeva S. E. Evstifeeva V. G. Vilkov O. L. Barbarash O. A. Belova Yu. I. Grinshtein A. Yu. Efanov O. N. Kalachikova N. V. Kulakova O. P. Rotar I. A. Trubacheva D. V. Duplyakov R. A. Libis I. A. Viktorova A. N. Redko S. S. Yakushin S. A. Boytsov E. V. Shlyakhto O. M. Drapkina Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders Рациональная фармакотерапия в кардиологии population-based study non-high-density lipoprotein cholesterol cardiovascular risk esse-rf study |
| title | Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders |
| title_full | Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders |
| title_fullStr | Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders |
| title_full_unstemmed | Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders |
| title_short | Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders |
| title_sort | non high density lipoprotein cholesterol a modern benchmark for assessing lipid metabolism disorders |
| topic | population-based study non-high-density lipoprotein cholesterol cardiovascular risk esse-rf study |
| url | https://www.rpcardio.online/jour/article/view/2784 |
| work_keys_str_mv | AT sashalnova nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT vametelskaya nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT vakutsenko nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT ebyarovaya nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT avkapustina nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT gamuromtseva nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT gesvinin nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT yuabalanova nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT aeimaeva nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT seevstifeeva nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT vgvilkov nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT olbarbarash nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT oabelova nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT yuigrinshtein nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT ayuefanov nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT onkalachikova nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT nvkulakova nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT oprotar nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT iatrubacheva nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT dvduplyakov nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT ralibis nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT iaviktorova nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT anredko nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT ssyakushin nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT saboytsov nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT evshlyakhto nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders AT omdrapkina nonhighdensitylipoproteincholesterolamodernbenchmarkforassessinglipidmetabolismdisorders |